Cargando…
The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 [corrected]
Thirty-five patients with advanced malignant disease have been treated as outpatients with increasing doses (0.1-100 mcg) of interleukin 2 (IL2) by once daily self-administered subcutaneous (s.c.) injection, 5 days weekly for 8 weeks followed by a 4 week observation period. Systemic side effects wer...
Autores principales: | Stein, R. C., Malkovska, V., Morgan, S., Galazka, A., Aniszewski, C., Roy, S. E., Shearer, R. J., Marsden, R. A., Bevan, D., Gordon-Smith, E. C. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1991
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971786/ https://www.ncbi.nlm.nih.gov/pubmed/1997106 |
Ejemplares similares
-
Severe pneumomediastinum and subcutaneous emphysema subsequent to prolonged mechanical ventilation
por: Fidrocki, Diana M., et al.
Publicado: (2021) -
A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma.
por: Ahmed, F. Y., et al.
Publicado: (1996) -
Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.
por: Ravaud, A., et al.
Publicado: (1994) -
A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease.
por: Gottlieb, D. J., et al.
Publicado: (1989) -
Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial.
por: Gilleece, M. H., et al.
Publicado: (1992)